Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.4.2443

Utility of VEGF and sVEGFR-1 in Bronchoalveolar Lavage Fluid for Differential Diagnosis of Primary Lung Cancer  

Cao, Chao (Department of Respiratory Medicine, the Affiliated Hospital of School of Medicine, Ningbo University)
Sun, Shi-Fang (Department of Respiratory Medicine, the Affiliated Hospital of School of Medicine, Ningbo University)
Lv, Dan (Department of Respiratory Medicine, the Affiliated Hospital of School of Medicine, Ningbo University)
Chen, Zhong-Bo (Department of Respiratory Medicine, the Affiliated Hospital of School of Medicine, Ningbo University)
Ding, Qun-Li (Department of Respiratory Medicine, the Affiliated Hospital of School of Medicine, Ningbo University)
Deng, Zai-Chun (Department of Respiratory Medicine, the Affiliated Hospital of School of Medicine, Ningbo University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.4, 2013 , pp. 2443-2446 More about this Journal
Abstract
Published data have shown that the levels of vascular endothelial growth factor (VEGF) and soluble VEGF receptor-1 (sVEGFR-1) in plasma and pleural effusion might be usefulness for lung cancer diagnosis. Here, we performed a prospective study to investigate the utility of VEGF and sVEGFR-1 in bronchoalveolar lavage fluid (BALF) for differential diagnosis of primary lung cancer. A total of 56 patients with solitary pulmonary massed by chest radiograph or CT screening were enrolled in this study. BALF and plasma samples were obtained from all patients and analyzed for VEGF and sVEGFR-1 using a commercially available sandwich ELISA kit. The results showed that the levels of VEGF in BALF were significantly higher in patients with a malignant pulmonary mass compared with patients with a benign mass (P < 0.001). However, no significant difference of sVEGFR-1 in BALF was found between malignant and non-malignant groups (P = 0.43). With a cut-off value of 214 pg/ml, VEGF showed a sensitivity and specificity of 81.8% and 84.2%, respectively, in predicting the malignant nature of a solitary pulmonary mass. Our study suggests that VEGF is significantly increased in BALF among patients with lung cancer than in benign diseases. Measurement of VEGF in BALF might be helpful for differential diagnosis of primary lung cancer.
Keywords
Lung cancer; Bronchoalveolar lavage fluid; VEGF; sVEGFR-1;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Bugdayci G, Kaplan T, Sezer S, et al (2006). Matrix metalloproteinase-9 in broncho-alveolar lavage fluid of patients with non-small cell lung cancer. Exp Oncol, 28, 169-71.
2 Cao C, Zhang YM, Wang R, et al (2011). Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis. Chin Med J (Engl), 124, 2203-8.
3 Charalabopoulos K, Karakosta A, Bablekos G, et al (2007). CEA levels in serum and BAL in patients suffering from lung cancer: correlation with individuals presenting benign lung lesions and healthy volunteers. Med Oncol, 24, 219-25.   DOI   ScienceOn
4 Cremades MJ, Men ndez R, Pastor A, Llopis R, Aznar J (1998). Diagnostic value of cytokeratin fragment 19 (CYFRA 21-1) in bronchoalveolar lavage fluid in lung cancer. Respir Med, 92, 766-71.   DOI   ScienceOn
5 Denizot Y, Leguyader A, Cornu E, et al (2007). Release of soluble vascular endothelial growth factor receptor-1 (sFlt-1) during coronary artery bypass surgery. J Cardiothorac Surg, 2, 38.   DOI   ScienceOn
6 Domaga_a-Kulawik J, Hoser G, Safianowska A, Grubek-Jaworska H, Chazan R (2006). Elevated TGF-beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Arch Immunol Ther Exp, 54, 143-7.   DOI   ScienceOn
7 Ellis JR, Gleeson FV (2001). Lung cancer screening. Br J Radiol, 74, 478-85.   DOI
8 Emad A, Emad V (2008). The value of BAL fluid LDH level in differentiating benign from malignant solitary pulmonary nodules. J Cancer Res Clin Oncol, 134, 489-93.   DOI
9 Ferrara N (2002). VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer, 2, 795-803.   DOI   ScienceOn
10 Ferrara N, Davis-Smyth T (1997). The biology of vascular endothelial growth factor. Endocr Rev, 18, 4-25.   DOI   ScienceOn
11 Fiorelli A, Morgillo F, Fasano M, et al (2013). The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion. Interact Cardiovasc Thorac Surg, 16, 263-9.   DOI
12 Hooper CE, Elvers KT, Welsh GI, Millar AB, Maskell NA (2012). VEGF and sVEGFR-1 in malignant pleural effusions: association with survival and pleurodesis outcomes. Lung Cancer, 77, 443-9.   DOI   ScienceOn
13 Ilhan N, Ilhan N, Deveci F (2004). Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types. Clin Biochem, 37, 840-5.   DOI   ScienceOn
14 Karahalli E, Yilmaz A, T rker H, Ozvaran K (2001). Usefulness of various diagnostic techniques during fiberoptic bronchoscopy of endoscopically visible lung cancer: should cytologic examinations be performed routinely. Respiration, 68, 611-4.   DOI   ScienceOn
15 Kishiro I, Kato S, Fuse D, Yoshida T, Machida S, Kaneko N (2002). Clinical significance of vascular endothelial growth factor in patients with primary lung cancer. Respirology, 7, 93-8.   DOI   ScienceOn
16 Marcus PM (2001).Lung cancer screening: an update. J Clin Oncol, 19, S83-6.
17 Mazzone P, Jain P, Arroliga AC, Matthay RA (2002). Bronchoscopy and needle biopsy techniques for diagnosis and staging of lung cancer. Clin Chest Med, 23, 137-58.   DOI
18 Ohta Y, Ohta N, Tamura M, et al (2002). Vascular endothelial growth factor expression in airways of patients with lung cancer: a possible diagnostic tool of responsive angiogenic status on the host side. Chest, 121, 1624-7.   DOI   ScienceOn
19 Shibuya M (2011). Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti-and Pro-Angiogenic Therapies. Genes Cancer, 2, 1097-105.   DOI   ScienceOn
20 Sun SF, Huang DB, Cao C, Deng ZC (2013). Polymorphism of VEGF-460C/T associated with the risk and clinical characteristics of lung cancer in Chinese population. Med Oncol, 30, 410.   DOI   ScienceOn
21 Swidzi_ska E, Ossoli_ska M, Naumnik W, et al (2004). Circulating VEGF and its soluble receptor sVEGFR-1 in patients with lung cancer. Pneumonol Alergol Pol, 72, 389-94.
22 Tamura M, Ohta Y, Nakamura H, Oda M, Watanabe G (2002). Diagnostic value of plasma vascular endothelial growth factor as a tumor marker in patients with non-small cell lung cancer. Int J Biol Markers, 17, 275-9.
23 Wang Z, Chen Y, Li X, et al (2012). Expression of VEGF-C/ VEGFR-3 in human laryngeal squamous cell carcinomas and its significance for lymphatic metastasis. Asian Pac J Cancer Prev, 13, 27-31.   DOI   ScienceOn
24 Wingo PA, Ries LA, Giovino GA, et al (1999). Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst, 91, 675-90.   DOI   ScienceOn